Use of: (a) 21 dosage forms comprising estrogen and progestin, wherein: the estrogen in each of the dosage forms is present in a daily amount equivalent to 5 µg to 50 µg of ethinyl estradiol, and the progestin in each of the dosage forms is present in a daily amount equivalent to 0.05 mg to 1.5 mg of desogestrel and (b) 7 dosage forms comprising estrogen, wherein the estrogen in each of the dosage forms is present in a daily amount equivalent to 5µg to 50 µg of ethinyl estradiol in the manufacture of a medicament for use in the treatment of a premenstrual symptom or for use in diminishing an estrogen withdrawal symptom, wherein each of the 21 dosage forms in (a) is administered sequentially and continuously each day for 21 consecutive days followed consecutively by sequential and continuous administration of each of the 7 dosage forms in (b) each day for 7 consecutive days.
